CDK4 and liposarcoma: Given that a high percentage of well-differentiated (WD) and de-differentiated (DD) liposarcoma (LPS) demonstrate CDK4 amplification, recent trials described below have been conducted to evaluate the utility of CDK4/6 inhibitors in the treatment of LPS.